Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing significant efficacy. These results were presented during the press briefing ahead of the 2026 ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for colorectal cancer (CRC) in patients with type 2 diabetes, with and without overweight or obesity, according ...
The GLP-1 RA cohort had significantly lower odds of developing early-onset colorectal cancer (0.4 vs 0.7%) vs the no GLP-1 RA cohort. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 ...
Cardiff Oncology completed patient enrollment in the Phase 2 CRDF-004 trial for RAS-mutated mCRC, with data expected in 2025. Cardiff Oncology, Inc. announced the completion of patient enrollment in ...
Arnold D, Lueza B, Douillard JY, et al: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback